ArticleResearch square2025
Connexin Restrains EMT by Dual-Domain Mechanisms to Preserve Epithelial Identity.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Epithelial-mesenchymal transition (EMT) contributes to fibrotic disease in multiple organs and underlies post-surgical complications such as posterior capsule opacification (PCO), the leading cause of vision loss following cataract surgery. The molecular mechanisms that preserve epithelial integrity and restrain EMT remain poorly defined. Connexins are conventionally regarded as gap junction proteins mediating intercellular communication, but here we identify connexin 50 (Cx50) as a previously unrecognized key regulator of EMT. Using in vitro, ex vivo, and in vivo chick and mouse models, we show that transforming growth factor-β2 (TGF-β2) downregulates Cx50 and induces EMT markers including α-smooth muscle actin and fibronectin, changes reversed by Cx50 overexpression. Mechanistically, the extracellular E2 domain of Cx50 mediates adhesive interactions that limit epithelial migration and EMT, while the C-terminal domain stabilizes β-catenin-E-cadherin complexes and prevents TGF-β2-driven E-cadherin loss and β-catenin nuclear translocation. Dominant-negative E2 mutants abolish protection, and Cx50 knockout mice exhibit accelerated EMT after extracapsular lens extraction. These findings redefine connexins beyond their classical role as gap junction proteins, establishing Cx50 as a dual-domain regulator of EMT and epithelial plasticity with implications for fibrotic responses in ocular and other epithelial tissues.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.